Explore myeloma studies
Find registry records by therapy, target, phase, status or country. Open a study to review its details and original ClinicalTrials.gov record.
906 matching studies · filters are included in this page’s URL
Active means recruiting, active but not recruiting, not yet recruiting, or enrolling by invitation. Country filters describe registered sites, not confirmed local availability. Target and modality matches can refer to any study arm, including comparators.
| Study | Phase | Status | Lead sponsor | Primary completion |
|---|---|---|---|---|
| NCT05572515Teclistamab · Pomalidomide · Bortezomib | Phase 3 | Active Not Recruiting | Janssen Research & Development, LLCIndustry | Oct 13, 2025 |
| NCT05870917anti-BCMA CAR-T · VRD-based Regimen | Phase 2 | Active Not Recruiting | Institute of Hematology & Blood Diseases Hospital, ChinaOther | Sep 18, 2025 |
| NCT05979363anti-BCMA CAR-T · VRD-based regimen | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, ChinaOther | Dec 1, 2026 |
| NCT06948084Biospecimen Collection · Bone Marrow Biopsy · Carfilzomib | Phase 2 | Recruiting | National Cancer Institute (NCI)Nih | Feb 28, 2028 |
| NCT06971380HBI0101 CART | Phase 2 | Recruiting | Polina StepenskyOther | May 15, 2028 |
| NCT07009899Linvoseltamab | Phase 2 | Recruiting | Medical College of WisconsinOther | Feb 1, 2028 |
| NCT07221032FT836 CAR T cells (1 x 10^8 cells per dose) · FT836 CAR T cells (3 x 108 cells per dose) · FT836 CAR T cells (up to 9 x 108 cells per dose) | Phase 1 | Recruiting | Medical College of WisconsinOther | Mar 2028 |
| NCT07222761Linvoseltamab · Carfilzomib · Daratumumab | Phase 3 | Recruiting | Regeneron PharmaceuticalsIndustry | May 21, 2029 |
| NCT07239323Invivo CAR-T | Phase 1 | Recruiting | Chongqing Precision Biotech Co., LtdIndustry | Dec 31, 2027 |
| NCT07393282Linvoseltamab · Daratumumab | Phase 3 | Recruiting | Regeneron PharmaceuticalsIndustry | Jul 27, 2033 |